Information Provided By: 
Fly News Breaks for February 2, 2017
CNMD
Feb 2, 2017 | 08:56 EDT
Needham analyst Mike Matson lowered his price target for CONMED to $48 from $53 after the company's Q4 revenue beat but EPS missed consensus and guidance were below consensus due partly to an increased currency headwind. Nonetheless, the analyst reiterates a Buy rating on the shares as he continues to expect revenue growth to increase in 2017 as SurgiQuest growth becomes organic and the Edge ablation system improves Orthopedics growth.
News For CNMD From the Last 2 Days
CNMD
Apr 25, 2024 | 07:09 EDT
CNMD
Apr 25, 2024 | 07:00 EDT
Piper Sandler analyst Matt O'Brien lowered the firm's price target on Conmed to $95 from $100 and keeps an Overweight rating on the shares. The firm notes Conmed reported Q1 2024 results that beat slightly on the top- and bottom-line. The General Surgery business drove all the upside on the top-line in the quarter. Piper also highlights that management lowered guidance for the year due to FX, but it is essentially unchanged when adjusting for this.
CNMD
Apr 24, 2024 | 18:48 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here
CNMD
Apr 24, 2024 | 16:07 EDT
CNMD
Apr 24, 2024 | 16:05 EDT
CNMD
Apr 24, 2024 | 16:04 EDT
Reports Q1 revenue $312.3M, consensus $306.78M. "2024 is off to a solid start as the quarter delivered our expected top- and bottom-line growth and margin expansion," commented Curt R. Hartman, CONMED's Chair of the Board, President, and Chief Executive Officer. "We remain well positioned with a compelling and diverse portfolio to drive continued growth across the markets we serve."
